Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T A Yap

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
British Journal of Cancer|July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyL R Molife, P C Fong, L Paccagnella, et al.
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2023
HER2-low expression in patients with advanced or metastatic solid tumorsB Uzunparmak, C Haymaker, G Raso, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
British Journal of Cancer|July 15, 2010
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label studyL R Molife, P C Fong, L Paccagnella, et al.
British Journal of Cancer|April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumoursT A Yap, H Cortes-Funes, H Shaw, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2022
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022D Araujo, A Greystoke, S Bates, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2023
HER2-low expression in patients with advanced or metastatic solid tumorsB Uzunparmak, C Haymaker, G Raso, et al.
Pageof 2